Fractionated Stereotactic Radiotherapy (FSR) and Stereotactic Radiosurgery (SRS) for the Treatment of Nonacoustic Cranial Nerve Schwannomas

2007 ◽  
Vol 69 (3) ◽  
pp. S164
Author(s):  
T.N. Showalter ◽  
M. Werner-Wasik ◽  
W.J. Curran ◽  
D.P. Friedman ◽  
M. Machtay ◽  
...  
Keyword(s):  
Stereotactic Radiosurgery ◽  
Stereotactic Radiotherapy ◽  
Cranial Nerve ◽  
Fractionated Stereotactic Radiotherapy

STEREOTACTIC RADIOSURGERY AND FRACTIONATED STEREOTACTIC RADIOTHERAPY FOR THE TREATMENT OF NONACOUSTIC CRANIAL NERVE SCHWANNOMAS

Neurosurgery ◽  
2008 ◽  
Vol 63 (4) ◽  
pp. 734-740 ◽  
Author(s):  
Timothy N. Showalter ◽  
Maria Werner-Wasik ◽  
Walter J. Curran ◽  
David P. Friedman ◽  
Xia Xu ◽  
...  
Keyword(s):  
Stereotactic Radiosurgery ◽  
Stereotactic Radiotherapy ◽  
Cranial Nerve ◽  
Cranial Nerves ◽  
Symptomatic Improvement ◽  
Fractionated Stereotactic Radiotherapy ◽  
Tumor Control ◽  
Median Dose ◽  
Significant Difference

ABSTRACT OBJECTIVE To review outcomes after fractionated stereotactic radiotherapy (FSR) and stereotactic radiosurgery (SRS) for nonacoustic cranial nerve schwannomas. METHODS We reviewed medical records of 39 patients who received FSR or SRS for nonacoustic cranial nerve schwannomas at our institution during the period from 1996 to 2007. RESULTS Tumors involved Cranial Nerves V (n = 19), III (n = 2), VI (n = 3), VII (n = 5), IX (n = 2), X (n = 5), and XII (n = 2) and the cavernous sinus (n = 1). Irradiation was performed after partial resection, biopsy, or no previous surgery in 16, 2, and 21 patients, respectively. Twenty-four patients received FSR, delivered in 1.8- to 2.0-Gy fractions to a median dose of 50.4 Gy (range, 45.0–54.0 Gy). Fifteen patients received SRS to a median dose of 12.0 Gy (range, 12–15 Gy). Mild acute toxicity occurred in 23% of the patients. The 2-year actuarial tumor control rate after FSR and SRS was 95%. The median follow-up period was 24 months. Changes in cranial nerve deficits after stereotactic irradiation were analyzed for patients with follow-up periods greater than 12 months (n = 26); cranial nerve deficits improved in 50%, were stable in 46%, and worsened in 4% of the patients. No significant difference was observed for FSR compared with SRS with regard to local control or to improvement of cranial nerve-related symptoms (P = 0.17). CONCLUSION SRS and FSR are both well-tolerated treatments for nonacoustic cranial nerve schwannomas, providing excellent tumor control and a high likelihood of symptomatic improvement.

Fractionated Stereotactic Radiotherapy For the Treatment of Large Arteriovenous Malformations with or without Previous Partial Embolization

Neurosurgery ◽  
2004 ◽  
Vol 55 (3) ◽  
pp. 519-531 ◽  
Author(s):  
Erol Veznedaroglu ◽  
David W. Andrews ◽  
Ronald P. Benitez ◽  
M. Beverly Downes ◽  
Maria Werner-Wasik ◽  
...  
Keyword(s):  
Stereotactic Radiosurgery ◽  
Stereotactic Radiotherapy ◽  
Arteriovenous Malformations ◽  
Three Dimensional ◽  
Late Complications ◽  
Fractionated Stereotactic Radiotherapy ◽  
Medical Systems ◽  
Significant Treatment ◽  
Lost To Follow Up

Abstract OBJECTIVE: Despite the success of stereotactic radiosurgery, large inoperable arteriovenous malformations (AVMs) of 14 cm3 or more have remained largely refractory to stereotactic radiosurgery, with much lower obliteration rates. We review treatment of large AVMs either previously untreated or partially obliterated by embolization with fractionated stereotactic radiotherapy (FSR) regimens using a dedicated linear accelerator (LINAC). METHODS: Before treatment, all patients were discussed at a multidisciplinary radiosurgery board and found to be suitable for FSR. All patients were evaluated for pre-embolization. Those who had feeding pedicles amenable to glue embolization were treated. LINAC technique involved acquisition of a stereotactic angiogram in a relocatable frame that was also used for head localization during treatment. The FSR technique involved the use of six 7-Gy fractions delivered on alternate days over a 2-week period, and this was subsequently dropped to 5-Gy fractions after late complications in one of seven patients treated with 7-Gy fractions. Treatments were based exclusively on digitized biplanar stereotactic angiographic data. We used a Varian 600SR LINAC (Varian Medical Systems, Inc., Palo Alto, CA) and XKnife treatment planning software (Radionics, Inc., Burlington, MA). In most cases, one isocenter was used, and conformality was established by non-coplanar arc beam shaping and differential beam weighting. RESULTS: Thirty patients with large AVMs were treated between January 1995 and August 1998. Seven patients were treated with 42-Gy/7-Gy fractions, with one patient lost to follow-up and the remaining six with previous partial embolization. Twenty-three patients were treated with 30-Gy/5-Gy fractions, with two patients lost to follow-up and three who died as a result of unrelated causes. Of 18 evaluable patients, 8 had previous partial embolization. Mean AVM volumes at FSR treatment were 23.8 and 14.5 cm3, respectively, for the 42-Gy/7-Gy fraction and 30-Gy/5-Gy fraction groups. After embolization, 18 patients still had AVM niduses of 14 cm3 or more: 6 in the 7-Gy cohort and 12 in the 5-Gy cohort. For patients with at least 5-year follow-up, angiographically documented AVM obliteration rates were 83% for the 42-Gy/7-Gy fraction group, with a mean latency of 108 weeks (5 of 6 evaluable patients), and 22% for the 30-Gy/5-Gy fraction group, with an average latency of 191 weeks (4 of 18 evaluable patients) (P = 0.018). For AVMs that remained at 14 cm3 or more after embolization (5 of 6 patients), the obliteration rate remained 80% (4 of 5 patients) for the 7-Gy cohort and dropped to 9% for the 5-Gy cohort. A cumulative hazard plot revealed a 7.2-fold greater likelihood of obliteration with the 42-Gy/7-Gy fraction protocol (P = 0.0001), which increased to a 17-fold greater likelihood for postembolization AVMs of 14 cm3 or more (P = 0.003). CONCLUSION: FSR achieves obliteration for AVMs at a threshold dose, including large residual niduses after embolization. With significant treatment-related morbidities, further investigation warrants a need for better three-dimensional target definition with higher dose conformality.

scholarly journals Radiosurgery and stereotactic radiotherapy with cyberknife system for meningioma treatment

2017 ◽  
Vol 31 (1) ◽  
pp. 18-26 ◽  
Author(s):  
Rossella Di Franco ◽  
Valentina Borzillo ◽  
Vincenzo Ravo ◽  
Sara Falivene ◽  
Francesco Jacopo Romano ◽  
...  
Keyword(s):  
Disease Control ◽  
Stereotactic Radiosurgery ◽  
Local Control ◽  
Stereotactic Radiotherapy ◽  
Histological Grade ◽  
Fractionated Stereotactic Radiotherapy ◽  
Subtotal Resection ◽  
Local Disease ◽  
Local Disease Control ◽  
The Impact

Objective The aim of this work was to evaluate the impact of stereotactic radiosurgery/fractionated stereotactic radiotherapy with the Cyberknife system on local disease control, clinical outcome and toxicity in patients with meningioma, according to the site and histological grade of lesion. From January 2013 to April 2017, 52 patients with intracranial meningiomas were treated with the Cyberknife system. Twenty-four patients had undergone previous surgery: 38% gross total resection, 10% subtotal resection; 27 patients underwent no surgery; 22 patients had a recurrence of meningioma. Methods Radiosurgery was used for lesions smaller than 2 cm, stereotactic radiotherapy for lesions larger than 2 cm, or smaller but close to a critical site such as the optical chiasm, optic pathway or brainstem. Results Local control and clinical outcomes were analysed. Median follow-up was 20 months: six patients died, one after re-surgery died from post-surgical sepsis, three from heart disease. Progression-free survival had a mean value of 38.3 months and overall survival of 41.6 months. We evaluated at 12 months 28 patients (100% local control); at 24 months 19 patients (89% local control); at 36 months nine patients (89% local control). At baseline, 44/52 patients (85%) were symptomatic: 19 visual disorders, 17 motor disorders, six hearing disorders, 10 headache and six epilepsy. Visual symptoms remained unchanged in 52%, improved in 32%, resolved in 16%. Headache was improved in 40%, resolved in 10%, unchanged in 50%. Epilepsy was resolved in 17%, unchanged in 33%, worsened in 33%. Conclusions Stereotactic radiosurgery/fractionated stereotactic radiotherapy with Cyberknife provides a good local disease control, improving visual, hearing and motor symptoms.

Hearing Preservation for Vestibular Schwannomas Treated with Stereotactic Radiosurgery or Fractionated Stereotactic Radiotherapy

2019 ◽  
Vol 129 ◽  
pp. e303-e310 ◽  
Author(s):  
Methma Udawatta ◽  
Isabelle Kwan ◽  
Komal Preet ◽  
Thien Nguyen ◽  
Vera Ong ◽  
...  
Keyword(s):  
Stereotactic Radiosurgery ◽  
Stereotactic Radiotherapy ◽  
Hearing Preservation ◽  
Fractionated Stereotactic Radiotherapy ◽  
Vestibular Schwannomas

Preservation of Cranial Nerve Function after Treatment of Acoustic Neurinomas with Fractionated Stereotactic Radiotherapy

1995 ◽  
Vol 64 (4) ◽  
pp. 165-182 ◽  
Author(s):  
David W. Andrews ◽  
Craig L. Silverman ◽  
Jon Glass ◽  
Beverly Downes ◽  
Richard J. Riley ◽  
...  
Keyword(s):  
Stereotactic Radiotherapy ◽  
Cranial Nerve ◽  
Fractionated Stereotactic Radiotherapy ◽  
Nerve Function ◽  
Cranial Nerve Function ◽  
Acoustic Neurinomas

A Comparative Study of Stereotactic Radiosurgery, Hypofractionated, and Fractionated Stereotactic Radiotherapy in the Treatment of Skull Base Meningioma

2014 ◽  
Vol 37 (3) ◽  
pp. 255-260 ◽  
Author(s):  
Jeannie Han ◽  
Michael R. Girvigian ◽  
Joseph C. T. Chen ◽  
Michael J. Miller ◽  
Kenneth Lodin ◽  
...  
Keyword(s):  
Comparative Study ◽  
Skull Base ◽  
Stereotactic Radiosurgery ◽  
Stereotactic Radiotherapy ◽  
Fractionated Stereotactic Radiotherapy ◽  
Skull Base Meningioma
Sign in / Sign up

Export Citation Format

Share Document